Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alr.22706 | DOI Listing |
PLoS One
January 2025
Departamento de Salud Pública, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia.
Background: Mucosal leishmaniasis (ML) is a severe clinical form of leishmaniasis that is characterized by the destruction of the nasal and/or the oral mucosae and appears as a late complication in 5% to 10% of cutaneous leishmaniasis (CL) cases produced by species belonging to Leishmania (Viannia) subgenus. Some strains of Leishmania spp. carry an RNA virus known as Leishmania RNA virus (LRV) that may contribute to the appearance of ML.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Department of Basic Research, Ab & B Bio-Tech Co., Ltd. JS, Taizhou 225300, China.
Background/objectives: The H7N9 avian influenza virus (AIV) constitutes a novel subtype of influenza virus that has emerged within the past decade. Empirical studies have demonstrated that H7N9 AIV holds the potential to trigger a human pandemic. Vaccines constitute the sole armament available to humanity in combating influenza epidemics.
View Article and Find Full Text PDFCells
January 2025
Department of Otolaryngology, Tokyo Teishin Hospital, Tokyo 102-0071, Japan.
Background/objectives: This study evaluated changes in circadian clock genes and mitochondrial function in a lead (Pb)-induced toxicity model of an olfactory epithelial cell line.
Methods: The DBC1.2 olfactory dark basal cell line was used.
Ann Plast Surg
January 2025
Division of Plastic Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL.
Background: Nasal septal defects cause considerable morbidity and represent a challenging reconstructive problem. Traditional repair techniques have employed local intranasal tissues and allograft adjuncts. For large septal defects (>4-5 cm2), less than half are successfully resolved.
View Article and Find Full Text PDFAnn Allergy Asthma Immunol
January 2025
Intrommune Therapeutics, Inc., New York.
Background: Oral Mucosal Immunotherapy (OMIT) uses a specifically formulated toothpaste to deliver allergenic proteins to immunologically active areas of the oral cavity. This represents a new delivery mechanism with several features designed to improve food allergy desensitization. OMIT presents advantages over other approaches to allergy immunotherapy due to its targeted delivery and simplified administration.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!